Evaluation of N-Hydroxy-, N-Metoxy-, and N-Acetoxybenzoyl-Substituted Derivatives of Thymine and Uracil as New Substances for Prevention and Treatment of Long-Term Complications of Diabetes Mellitus


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

New uracil and thymine derivatives, N1-,N3- and N1,N3-(RO-benzoyl)-(1H,3H)-pyrimidine- 2,4-diones, were synthesized (RO- is hydroxy, acetoxy- or methoxy-group). The compounds were studied in a complex of in vitro tests for the ability to inhibit the development of long-term complications of diabetes. Their ability to cleave cross-links of proteins has been evaluated. The most significant ways of pharmacological correction of thrombosis, angio-, nephro-, encephalo-, and cardiopathy, antiglycation, chelating, and antiplatelet activities, have been established. The most active compound in terms of antiplatelet action, N1- hydroxybenzoyluracil, exceeded acetylsalicylic acid by ~44%. In terms of their ability to chelate copper (II) cations, all compounds (with the exception of 1,3-bis(3-hydroxybenzoyl)-(1H,3H)-pyrimidine-2,4-dione that was not not studied in this test) showed the activity, whose IC50 fell in the range between that for pioglitazone (44.1 μM) and pyridoxamine (136.7 μM) comparison drugs. The best antiglycation effect at the 1 mM concentration was observed for N1,N3-bismethoxy- and N1,N3-bisacetoxybenzoyl derivatives of thymine. The maximum activity to cleave cross-links of proteins (C = 1 mM), comparable to that of alagebrium, was established for 1,3-bis(4-methoxybenzoyl)uracil, for which also high rates of other estimated activities were noted. Thus, the N1-,N3- and N1,N3-(RO-benzoyl) derivatives of uracil and thymine are promising basiсs for creating drugs that suppress the development of long-term complications of diabetes.

Sobre autores

A. Spasov

Volgograd State Medical University; Volgograd Medical Scientific Center; Scientific Institute of Pharmacology of VSMU

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131; Volgograd, 400081; Volgograd, 400001

A. Brel

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

R. Litvinov

Volgograd State Medical University; Scientific Institute of Pharmacology of VSMU

Autor responsável pela correspondência
Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131; Volgograd, 400001

S. Lisina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

A. Kucheryavenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

Yu. Budaeva

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

O. Salaznikova

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

A. Rashchenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

D. Shamshina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

V. Batrakov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

A. Ivanov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
Rússia, Volgograd, 400131

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Ltd., 2018